08:00 , Feb 2, 2015 |  BC Week In Review  |  Company News

Astute, bioMerieux deal

Astute granted bioMerieux semi-exclusive, worldwide rights to develop and commercialize Astute’s NephroCheck test for early risk assessment of acute kidney injury on bioMerieux’s Vidas diagnostic platform. NephroCheck is an immunoassay for insulin-like growth factor (IGF)...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Company News

Ortho-Clinical Diagnostics sales and marketing update

Ortho-Clinical launched the NephroCheck testing system in the U.S. to assess the risk of patients ages 21 years and older developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Financial News

Astute completes venture financing

Astute Medical Inc. , San Diego, Calif.   Business: Diagnostic   Date completed: 2014-10-09   Type: Venture financing   Raised: Not disclosed   Investor: CRG   Note: The company received an undisclosed portion of a...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

NephroCheck test regulatory update

FDA granted 510(k) clearance to Astute's NephroCheck Test System to assess the risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test. The product is...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Astute, Ortho-Clinical Diagnostics deal

Astute granted Ortho-Clinical Diagnostics exclusive, commercialization rights to the NephroCheck test and the Astute140 Meter in 11 countries in the EU and the U.S. The deal covers Austria, Belgium, France, Germany, Italy, Luxemburg, the Netherlands,...
07:00 , May 6, 2013 |  BioCentury  |  Finance

Keep it small

Atlas Venture decided to stay small with its oversubscribed ninth fund, raising $265 million that will primarily go towards seeding biotech and technology startups. Absent from the shopping list are young diagnostic companies, as the...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Company News

Astute sales and marketing update

Astute launched its NephroCheck test in Europe to determine the risk of acute kidney injury (AKI) in critically ill patients. The test is an immunoassay of two undisclosed biomarkers. The company did not disclose the...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Financial News

Astute completes venture financing

Astute Medical Inc. , San Diego, Calif.   Business: Diagnostic   Date completed: 6/7/12   Type: Venture financing   Raised: $40.4 million   Investors: MPM Capital; Kaiser Permanente Ventures; De Novo Ventures; Delphi Ventures; Domain...
00:28 , Jun 8, 2012 |  BC Extra  |  Financial News

Astute Medical raises $40.4M in C round

Diagnostic company Astute Medical Inc. (San Diego, Calif.) raised $40.4 million in a series C round led by new investor MPM Capital. Kaiser Permanente Ventures, also a new investor, joined existing investors De Novo Ventures;...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Financial News

Astute financial update

Astute Medical raised $13 million in an extension of a series B. Last May, Astute raised $26.5 million in the round. Astute Medical Inc. , San Diego, Calif.   Business: Diagnostic   Date announced: 3/8/11...